FindTrial
Sign In

Adverse drug reaction of SGLT2 inhibitors

Real-world safety assessment of SGLT2 inhibitors: an observational study in diverse patient population - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067860
Enrollment
192
Registered
2024-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I240- Acute coronary thrombosis not resulting in myocardial infarction Health Condition 2: N18- Chronic kidney disease (CKD) Health Condition 3: E08- Diabetes mellitus due to underlying condition

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged >=18 years newly initiated on SGLT2 inhibitors as per standard protocol.

Exclusion criteria

Exclusion criteria: 1.Those patients who are already on SGLT2 inhibitors 2.Patients on cancer chemotherapy, retroviral drugs and glucocorticoids 3.Pregnant females and lactating mothers 4.Patients refusing to participate in the study

Design outcomes

Primary

MeasureTime frame
To evaluate serious and non-serious adverse effects of SGLT2 inhibitors in diabetic and non-diabetic populationTimepoint: 6months,1year,1.5years.—

Secondary

MeasureTime frame
To analyze the usage of SGLT2 inhibitors as per prescription in diabetic & non-diabetic populationTimepoint: 6months,1year,1.5years.—

Countries

India

Contacts

Public ContactDr Meena Kumari K

Kasturba Medical College

meena.kumari@manipal.edu08202922365

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026